NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in ...

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company’s ...

As of 09:30 CEST. Market open. On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's ...

Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) today and set a price target of $25.00.

Fazio reported being an invited speaker for Novartis and Ipsen; serving on advisory boards for Novartis, Ipsen, MSD, and Merck; serving as a principal investigator of trials for 4Sc, Astellas, BeiGene ...

U.S. stocks were mixed after the close on Monday, as gains in the Telecoms, Oil & Gas and Financials sectors led shares ...